Skip to main content
. 2012 Jun 26;23(10):1054–1064. doi: 10.1089/hum.2012.030

FIG. 1.

FIG. 1.

Pmel T cells are weakly effective against B16ova. (A) C57BL/6 mice (8 mice/group) were challenged subcutaneously with 5×105 B16ova cells. PBS or 1×107 in vitro activated T cells were administered intravenously 7 days later. Data are representative of three independent experiments. (B) Intracellular staining for gp100 protein in B16ova cells (gp100, dashed histogram; secondary antibody alone, shaded histogram). (C) Activated OT-I or Pmel T cells were cultured with SIINFEKL peptide, mgp100 peptide, hgp100 peptide, or B16ova cells for 24 hr. IFNγ release was measured by ELISA of the supernatants. (D, E) Activated Pmel (D) or OT-I (E) T cells were used as effectors in a chromium release assay. Targets were B16ova cells with or without exogenous gp100 peptides, or B16 cells. (F) H-2Db expression on B16ova tumor cells (H-2Db, dashed histogram; isotype control, shaded histogram). (G) Wild-type C57BL/6 mice or TCR-transgenic Pmel mice (8 mice/group) were challenged with B16ova as in (A) and received no therapy. Data are representative of two experiments. *p<0.05 for all analyses.